loading...| Preferred Name |
Oprelvekin |
|
| Synonyms |
Adipogenesis Inhibitory Factor recombinant human interleukin-11 Interleukin 11 Recombinant Human Interleukin-11 Interleukin-11-Recombinant Recombinant Interleukin-11 Interleukin-11 IL-11 Neumega OPRELVEKIN Oprelvekin oprelvekin rhIL-11 |
|
| Definitions |
A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin 11 (IL-11). Secreted by bone marrow stromal cells and a number of mesenchymal cells, IL-11 binds to and activates its cell-surface receptor, promoting primary and secondary immune responses, modulating antigen-specific antibody reactions, and preventing apoptotic cell death. This agent also stimulates the T-cell-dependent development of IgG-secreting B-cells in spleen cell cultures and may be an important regulator of megakaryocytopoiesis. (NCI04) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1303 |
|
| Accepted_Therapeutic_Use_For |
Chemotherapy-related thrombocytopenia |
|
| ALT_DEFINITION |
A drug used to increase the number of blood cells, especially platelets, in some cancer patients receiving chemotherapy. Neumega is a form of interleukin-11 (a cytokine normally made by support cells in the bone marrow) that is made in the laboratory. It is a type of biological response modifier. |
|
| CAS_Registry |
145941-26-0 |
|
| code |
C1303 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 |
|
| Contributing_Source |
CTRP FDA HemOnc |
|
| DEFINITION |
A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin 11 (IL-11). Secreted by bone marrow stromal cells and a number of mesenchymal cells, IL-11 binds to and activates its cell-surface receptor, promoting primary and secondary immune responses, modulating antigen-specific antibody reactions, and preventing apoptotic cell death. This agent also stimulates the T-cell-dependent development of IgG-secreting B-cells in spleen cell cultures and may be an important regulator of megakaryocytopoiesis. (NCI04) |
|
| Display_Name |
Oprelvekin |
|
| FDA_UNII_Code |
HM5641GA6F |
|
| FULL_SYN |
Adipogenesis Inhibitory Factor recombinant human interleukin-11 Interleukin 11 Recombinant Human Interleukin-11 Interleukin-11-Recombinant Recombinant Interleukin-11 Interleukin-11 IL-11 Neumega OPRELVEKIN Oprelvekin oprelvekin rhIL-11 |
|
| label |
Oprelvekin |
|
| Legacy Concept Name |
Therapeutic_Interleukin-11 |
|
| NCI_Drug_Dictionary_ID |
42365 |
|
| PDQ_Closed_Trial_Search_ID |
42365 |
|
| PDQ_Open_Trial_Search_ID |
42365 |
|
| Preferred_Name |
Oprelvekin |
|
| prefixIRI |
Thesaurus:C1303 |
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance Immunologic Factor |
|
| UMLS_CUI |
C0537670 |
|
| subClassOf |